Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 17/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CLK2 | P49760 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14373361 | 0.91 | RAB9A (0.57) | CXCR3MEN1KMT2ACLK2DYRK1A | |
| SCHEMBL14373362 | 0.90 | CXCR3 (0.62) | CXCR3MEN1KMT2ACLK2DYRK1A | |
| SCHEMBL14470749 | 0.89 | CXCR3 (0.53) | CXCR3MEN1KMT2ACLK2DYRK1A | |
| SCHEMBL14373342 | 0.88 | CXCR3 (0.72) | CXCR3MEN1KMT2ACLK2DYRK1A | |
| SCHEMBL14373364 | 0.87 | CXCR3 (0.53) | CXCR3MEN1KMT2ACLK2DYRK1A | |
| SCHEMBL14373298 | 0.81 | CXCR3 (1.00) | CXCR3MEN1KMT2ACLK2DYRK1A | |
| SCHEMBL14373346 | 0.80 | CXCR3 (1.00) | CXCR3MEN1KMT2ACLK2DYRK1A | |
| SCHEMBL14373479 | 0.80 | CXCR3 (1.00) | CXCR3MEN1KMT2ACLK2DYRK1A | |
| SCHEMBL14373360 | 0.79 | CXCR3 (0.78) | CXCR3MEN1KMT2ACLK2DYRK1A | |
| SCHEMBL14373340 | 0.78 | RAB9A (0.62) | CXCR3MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | CXCR3 4743/4885MEN1 614/4885KMT2A 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.